News

Mayne Pharma today announced that it has entered into an agreement with Catalent to sell Metrics Contract Services for a total cash consideration of US$475 million (~A$679 million)

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA are pleased to announce that the US Food and Drug Administration (FDA) has granted approval of the Abbreviated New Drug Application (ANDA) for HALOETTE® (etonogestrel and ethinyl estradiol) vaginal hormonal contraceptive ring

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA are pleased to announce NEXTSTELLIS® (drospirenone and estetrol tablets) has been nominated for the 2022 Prix Galien USA Award for Best Pharmaceutical Agent.

Mayne Pharma Group Limited is pleased to announce a new strategic collaboration with GoodRx, a leading consumer-focused digital healthcare platform in the U.S. The collaborative initiative will deliver an enhanced direct-to-consumer program aimed at building awareness of NEXTSTELLIS® (E4/DRSP) oral contraceptive availability in the United States.

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA are pleased to announce NEXTSTELLIS® (14.2 mg of estetrol and 3 mg drospirenone tablets), a first-of-its kind oral contraceptive with a novel estrogen is now available in Australia.

Mayne Pharma Group Limited is pleased to announce that Mr Aaron Gray has been appointed as Chief Financial Officer (CFO), effective 29 August 2022.

Mayne Pharma Group Limited presentation at Wilsons Rapid Insights conference on 26 May 2022.

Mayne Pharma Group Limited is pleased to announce that its application for a Federal Government Modern Manufacturing Initiative (MMI) Grant has been successful.

Mayne Pharma Group Limited (ASX: MYX) is pleased to announce that Ann Custin has accepted an invitation to join the Board of Mayne Pharma, effective 23 March 2022.